en Gastroentrology Gastroentrology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:13.8pt"><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> The diagnosis of ulcerative colitis (UC) today is limited to a small number of biomarkers. Trimethylamine-N-oxide (TMAO) is the product of reactions resulting from the degradation of dietary-free choline, phosphatidylcholine, and carnitine metabolism by the intestinal microbiota. Earlier studies showed his involvement in the pathogenesis of UC. To study the association of TMAO with clinical, laboratory, and endoscopic indicators of UC activity. </span><br> <span style="line-height:13.8pt"><b><i><span style="color:blue">Methods:</span></i></b><span style="color:black"> an observational cross-sectional comparative study was conducted based on the NCJSC &ldquo;KMU&rdquo; clinic, Karaganda, Kazakhstan. High-performance liquid chromatography measured TMAO concentration in 63 patients with UC (age Me 37 (30-52) and 38 healthy individuals (age Me 38 (28.5-49.5)</span>.<span style="font-size:10.0pt"></span></span><br> <span style="line-height:13.8pt"><b><i><span style="color:blue">Results:</span></i></b><span style="color:black"> Median TMAO level in patients with UC-0.286 &mu;mol/l was significantly lower than in the control group Me 0.646 &mu;mol/l (p<0.0001). TMAO had significant differences in groups with clinically active and inactive colitis (P=0.003). TMAO correlated with disease activity by Montreal scale (r=-0.389, P=0.002) and severity of attack by Truelove-Witts (r=-0.301, P=0.027 respectively), patient&rsquo;s age (r=0.377, P=0.003), stool frequency (r=-0.427, P=0.001); laboratory parameters: WBC (r=-0.31, P=0.042), blood albumin (r=0.379, P=0.002) and fecal calprotectin (r=-0.314, P=0.022). TMAO did not differ between groups divided by the extent of the pathological process and endoscopic activity</span>.<span style="font-size:10.0pt"></span></span><br> <span style="line-height:13.8pt"><b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> in patients with UC, TMAO levels decrease compared with healthy individuals and differences in groups depend on the disease activity. These results give reason to consider changes in TMAO levels as a potential marker of UC and the severity of its course.<span style="font-size:10.0pt"></span></span></span></span><br> &nbsp; IBD, Inflammatory bowel diseases, Ulcerative colitis, Trimethylamine N-oxide, TMAO, Biomarkers. 114 125 http://caspjim.com/browse.php?a_code=A-10-3443-1&slc_lang=en&sid=1 Yelena Laryushina laryushina@qmu.kz 100319475328460050528 100319475328460050528 No NCJSC “Karaganda Medical University” Nadezhda Samoilova-Bedych samoylova@qmu.kz 100319475328460050529 100319475328460050529 Yes NCJSC, Karaganda Medical University, Karaganda, Kazakhstan Lyudmila Turgunova turgunova@qmu.kz 100319475328460050530 100319475328460050530 No NCJSC “Karaganda Medical University” Alexander Marchenko marchenko@qmu.kz 100319475328460050531 100319475328460050531 No NCJSC “Karaganda Medical University” Yermek Turgunov turgunov@qmu.kz 100319475328460050532 100319475328460050532 No NCJSC “Karaganda Medical University”